Literature DB >> 22399608

Cytotoxicity of activated natural killer cells and expression of adhesion molecules in small-cell lung cancer.

Tadashi Tsuchida1, Hiromichi Yamane, Nobuaki Ochi, Takayuki Tabayashi, Akio Hiraki, Naoyuki Nogami, Nagio Takigawa, Katsuyuki Kiura, Mitsune Tanimoto.   

Abstract

BACKGROUND/AIM: Although small-cell lung cancer (SCLC) is sensitive to anticancer agents, most patients with SCLC experience relapse and die within two years. Here, we examined the relationship between natural killer (NK) cells and adhesion molecules on SCLC cell lines.
MATERIALS AND METHODS: The expression levels of HLA class I, β2-microglobulin, Fas/Apo-1 receptor (FAS) and adhesion molecules on SCLC cell lines were examined by flow cytometry. The cytotoxicity of activated NK cells from SCLC patients was examined using (51)Cr-release assay.
RESULTS: HLA class I antigen and β2-microglobulin expression levels in SCLC cell lines were lower than those in healthy volunteers. SCLC cell lines were susceptible to lysis by activated NK cells but this showed no correlation with expression levels of adhesion molecules.
CONCLUSION: Target cell susceptibility to activated NK cells from five SCLC patients correlated with survival benefit; target cell susceptibility to activated NK cells may be a surrogate marker of outcome for patients with SCLC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22399608

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Immune checkpoint inhibitors in small cell lung cancer.

Authors:  Suchita Pakkala; Taofeek K Owonikoko
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

2.  Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines.

Authors:  Hiromichi Yamane; Hideko Isozaki; Masami Takeyama; Nobuaki Ochi; Kenichiro Kudo; Yoshihiro Honda; Tomoko Yamagishi; Toshio Kubo; Katsuyuki Kiura; Nagio Takigawa
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

Review 3.  Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors.

Authors:  Suchit H Patel; Andreas Rimner; Roger B Cohen
Journal:  Transl Lung Cancer Res       Date:  2017-04

Review 4.  Combining immunotherapy with radiation therapy in thoracic oncology.

Authors:  Shahed N Badiyan; Michael C Roach; Michael D Chuong; Stephanie R Rice; Nasarachi E Onyeuku; Jill Remick; Srinivas Chilukuri; Erica Glass; Pranshu Mohindra; Charles B Simone
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

5.  Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer.

Authors:  Xiao Ding; He Cao; Xiao Chen; Haofan Jin; Ziling Liu; Guanjun Wang; Lu Cai; Dan Li; Chao Niu; Huimin Tian; Lei Yang; Yuguang Zhao; Wei Li; Jiuwei Cui
Journal:  J Transl Med       Date:  2015-05-13       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.